Boehringer Ingelheim GmbH, of Ingelheim, Germany, said the European Commission has granted marketing authorization for Cyltezo, a biosimilar to Humira (adalimumab, Abbvie Inc.) for the treatment of multiple chronic inflammatory diseases in adults and children.